Compare WEN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | OCS |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1999 | N/A |
| Metric | WEN | OCS |
|---|---|---|
| Price | $8.16 | $29.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | $8.97 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 10.7M | 305.2K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $2,246,492,000.00 | N/A |
| Revenue This Year | $2.76 | $14.53 |
| Revenue Next Year | $1.07 | $691.13 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | ★ 2.98 | N/A |
| 52 Week Low | $6.73 | $14.00 |
| 52 Week High | $16.20 | $29.50 |
| Indicator | WEN | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 64.14 |
| Support Level | $6.73 | $28.05 |
| Resistance Level | $8.35 | $29.09 |
| Average True Range (ATR) | 0.46 | 1.01 |
| MACD | 0.06 | -0.22 |
| Stochastic Oscillator | 89.50 | 76.12 |
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.